About
VirXcel develops macrocyclic peptide-based antiviral therapeutics, focusing on intranasal treatments to prevent and mitigate respiratory viral infections such as SARS-CoV-2 by targeting conserved viral protein sites inaccessible to antibodies.
Explore VirXcel's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.